May 3, 2013 / 2:20 PM / 4 years ago

Bayer stops drug trial with haemophilia drug BAY 86-6150

1 Min Read

FRANKFURT, May 3 (Reuters) - Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.

"The hope that BAY 86-6150 might help patients with inhibitors to achieve better control of their disease could not be fulfilled due to the detection of a neutralizing antibody in the trial," the company said on Friday. (Reporting by Ludwig Burger)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below